MG
Mark C. Genovese
Elite in Psoriatic Arthritis

Dr. Mark C. Genovese

Psoriasis Clinic
Redwood City, CA
Elite
 in Psoriatic Arthritis
Specialties:Rheumatology
Experience:31 Years
Age:58
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Mark C. Genovese's experience treating your condition:
About Dr. Mark C. Genovese

Mark Genovese is a Rheumatologist in Redwood City, California. Genovese has been practicing medicine for over 31 years and is rated as an Elite expert by MediFind in the treatment of Psoriatic Arthritis. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis. He is licensed to treat patients in California. Genovese is currently accepting new patients.

His clinical research consists of co-authoring 164 peer reviewed articles and participating in 13 clinical trials in the past 15 years. In particular, he has co-authored 15 articles and participated in 1 clinical trial in the study of Psoriatic Arthritis.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Mark C. Genovese it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
450 Broadway St, Redwood City, CA 94063
Other Locations
900 Blake Wilbur Dr, Palo Alto, CA 94304
Background & Education
Graduate Institution
Johns Hopkins University School Of Medicine, 1992
Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Active, not recruiting
Publish Date: October 24, 2022
Intervention Type: Drug, Biological
Study Drugs: OtilimabTofacitinibcsDMARDs
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: August 11, 2022
Intervention Type: Drug, Biological
Study Drugs: GSK3196165SarilumabcsDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: OlokizumabMethotrexate
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 (Olokizumab) Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Enrollment Status: Active, not recruiting
Publish Date: January 27, 2022
Intervention Type: Drug
Study Drug: Sarilumab
Study Phase: Phase 2
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: April 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy
Enrollment Status: Completed
Publish Date: June 28, 2017
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Enrollment Status: Completed
Publish Date: January 24, 2017
Intervention Type: Biological
Study Phase: Phase 2
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
Enrollment Status: Withdrawn
Publish Date: February 05, 2016
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: August 05, 2008
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis
Enrollment Status: Completed
Publish Date: March 24, 2006
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials -
164 Total Publications
Safety and Efficacy of Filgotinib for Japanese Patients with RA and Inadequate Response to MTX: FINCH 1 52-Week Results and FINCH 4 48-Week Results.
Journal: Modern rheumatology
Published: April 13, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
VS
Vibeke Strand
Dr. Vibeke Strand
Rheumatology
Elite
Highly rated in
14
conditions
Rheumatology

VA Sierra Pacific Network

VA Palo Alto Health Care System - Palo Alto Division

3801 Miranda Ave, 
Palo Alto, CA 
 6.5 mi

Vibeke Strand is a Rheumatologist in Palo Alto, California. Strand has been practicing medicine for over 47 years and is rated as an Elite expert by MediFind in the treatment of Psoriatic Arthritis. She is also highly rated in 14 other conditions, according to our data. Her top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Tissue Biopsy. She is licensed to treat patients in California.

SR
Dr. Siba P. Raychaudhuri
Rheumatology
Elite
Highly rated in
6
conditions
Rheumatology

VA Sierra Pacific Network

VA Northern California

150 Muir Rd, 
Martinez, CA 
 35.5 mi

Siba Raychaudhuri is a Rheumatologist in Martinez, California. Raychaudhuri has been practicing medicine for over 40 years and is rated as a Distinguished expert by MediFind in the treatment of Psoriatic Arthritis. He is also highly rated in 6 other conditions, according to our data. His top areas of expertise are Psoriatic Arthritis, Psoriasis, Arthritis, Rheumatoid Arthritis (RA), and Tissue Biopsy. He is licensed to treat patients in California. Raychaudhuri is currently accepting new patients.

BG
Dr. Brittany L. Goss
Rheumatology
Distinguished
Highly rated in
19
conditions
Rheumatology

Providence Health & Services

3273 Claremont Way, 
Napa, CA 
 57.9 mi

Brittany Goss is a Rheumatologist in Napa, California. Goss has been practicing medicine for over 18 years and is rated as a Distinguished expert by MediFind in the treatment of Psoriatic Arthritis. She is also highly rated in 19 other conditions, according to our data. Her top areas of expertise are Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis (RA), and Rheumatoid Pneumoconiosis. She is licensed to treat patients in Florida and California. Goss is currently accepting new patients.